The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts.

The PI3K/Akt/mTOR pathway plays a role in various oncogenic processes in breast cancer and key pathway aberrations have been identified which drive the different molecular subtypes. Early drugs developed targeting this pathway produced some clinical success but were hampered by pharmacokinetics, tolerability and efficacy problems. This created a need for new PI3K pathway-inhibiting drugs, which would produce more robust results allowing incorporation into treatment regimens for breast cancer patients. In this review, the most promising candidates from the new generation of PI3K-pathway inhibitors is explored, presenting evidence from preclinical and early clinical research, as well as ongoing trials utilising these drugs in breast cancer cohorts. The problems hindering the development of drugs targeting the PI3K pathway are examined, which have created problems for their use as monotherapies. PI3K pathway inhibitor combinations therefore remains a dynamic research area, and their role in combination with immunotherapies and epigenetic therapies is also inspected.

• Publication year

  2018

• Venue

  Biochimica et biophysica acta. Reviews on cancer

• Publication date

  2018-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.bbcan.2018.08.001PMID 30318472
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Absorption, distribution, metabolism, and excretion of mTOR kinase inhibitor CC-223 in rats, dogs, and humans

  2019cited by this paper
• Epigenetics of Breast Cancer

  2018cited by this paper
• Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

  2018cited by this paper
• Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2018cited by this paper
• Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts

  2017cited by this paper
• PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux.

  2017cited by this paper
• A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

  2017cited by this paper
• Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ.

  2017cited by this paper
• Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).

  2017cited by this paper
• Leading Edge Review Primary , Adaptive , and Acquired Resistance to Cancer Immunotherapy

  2017cited by this paper
• TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies

  2017cited by this paper
• AKT Inhibition in Solid Tumors With AKT1 Mutations.

  2017cited by this paper
• A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

  2017cited by this paper
• Tumour heterogeneity and resistance to cancer therapies

  2017cited by this paper
• Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

  2017cited by this paper
• A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

  2017cited by this paper
• PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways

  2017cited by this paper
• A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.

  2017cited by this paper
• Preclinical study of CC223 as a potential anti-ovarian cancer agent

  2017cited by this paper
• A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors

  2017cited by this paper
• Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors

  2017cited by this paper
• mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment

  2017cited by this paper
• The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer.

  2017cited by this paper
• A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib

  2017cited by this paper
• PD‐L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation

  2017cited by this paper
• PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer

  2017cited by this paper
• Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anticancer Efficacy.

  2016cited by this paper
• A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

  2016cited by this paper
• Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.

  2016cited by this paper
• Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

  2016cited by this paper
• Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R

  2016cited by this paper
• Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

  2016cited by this paper
• Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha–Positive, PIK3CA-Mutant Breast Cancer

  2016cited by this paper
• Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.

  2016cited by this paper
• Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer

  2016cited by this paper
• Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.

  2016cited by this paper
• The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo.

  2016cited by this paper
• Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer

  2016cited by this paper
• Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers

  2016cited by this paper
• Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

  2016cited by this paper
• Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.

  2016cited by this paper
• Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

  2016cited by this paper
• Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.

  2016cited by this paper
• The novel mTORC1/2 dual inhibitor INK128 enhances radiosensitivity of breast cancer cell line MCF-7.

  2016cited by this paper
• Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC

  2016cited by this paper
• Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.

  2016cited by this paper
• Combination cancer immunotherapies tailored to the tumour microenvironment

  2016cited by this paper
• The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.

  2015cited by this paper
• A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma

  2015cited by this paper
• Enhanced Antitumor Activity of an Anti-5T4 Antibody–Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes

  2015cited by this paper
• PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

  2015cited by this paper
• PI3K/mTOR mediate mitogen-dependent HDAC1 phosphorylation in breast cancer: a novel regulation of estrogen receptor expression.

  2015cited by this paper
• Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors

  2015cited by this paper
• Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models

  2015cited by this paper
• A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies

  2015cited by this paper
• Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.

  2015cited by this paper
• Breaking up is hard to do: PI3K isoforms on the rebound.

  2015cited by this paper
• Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers.

  2015cited by this paper
• AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo

  2015cited by this paper
• Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer.

  2015cited by this paper
• A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer

  2015cited by this paper
• Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)

  2015cited by this paper
• Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy.

  2015cited by this paper
• Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

  2015cited by this paper
• A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells

  2015cited by this paper
• Targeting PI3 kinase in cancer.

  2015cited by this paper
• mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms

  2014cited by this paper
• Tumor–stroma crosstalk: targeting stroma in breast cancer

  2014cited by this paper
• Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

  2014cited by this paper
• Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

  2014cited by this paper
• PI3K and cancer: lessons, challenges and opportunities

  2014cited by this paper
• A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib

  2014cited by this paper
• Effects of targeting endometrial stromal sarcoma cells via histone deacetylase and PI3K/AKT/mTOR signaling.

  2014cited by this paper
• Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).

  2014cited by this paper
• Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences

  2014cited by this paper
• PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

  2014cited by this paper
• Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions

  2014cited by this paper
• Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

  2014cited by this paper
• Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.

  2014cited by this paper
• Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

  2014cited by this paper
• Identification of mTORC2 as a Necessary Component of HRG/ErbB2-Dependent Cellular Transformation

  2014cited by this paper
• Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

  2014cited by this paper
• Targeting Akt3 signaling in triple-negative breast cancer.

  2014cited by this paper
• LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.

  2014cited by this paper
• PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo

  2014cited by this paper
• Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

  2014cited by this paper
• Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer

  2014cited by this paper
• PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines

  2013cited by this paper
• Safety, pharmacokinetics, and preliminary activity of the alpha-specific PI3K inhibitor BYL719: Results from the first-in-human study.

  2013cited by this paper
• Abstract 5252: CC-223, a selective and potent mTOR kinase inhibitor, synergizes with 5-Aza and Erlotinib in eight NSCLC lines in vitro.

  2013cited by this paper
• BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

  2013cited by this paper
• A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma.

  2013cited by this paper
• Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

  2013cited by this paper
• Combined Targeting of mTOR and AKT Is an Effective Strategy for Basal-like Breast Cancer in Patient-Derived Xenograft Models

  2013cited by this paper
• Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.

  2013cited by this paper
• Downregulation of Erbin in Her2-overexpressing breast cancer cells promotes cell migration and induces trastuzumab resistance.

  2013cited by this paper
• Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations

  2013cited by this paper
• Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary

  2013cited by this paper
• Enhanced PI3K p110α Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110α-Selective PI3K Inhibitor

  2013cited by this paper
• Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS.

  2013cited by this paper

• Expanding landscape of kinase inhibitor research in 25 years (2001-2025) and advancements of next-generation kinase inhibitors.

  2026cites this paper
• Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition)

  2025cites this paper
• Synergistic therapeutic effects of pertuzumab and pyrrolitinib in HER-2-positive breast cancer: modulation of the PI3K/AKT pathway.

  2025cites this paper
• PFHxA and PFHxS promote breast cancer progression in 3D culture: MEX3C-associated immune infiltration revealed by bioinformatics and machine learning.

  2025cites this paper
• Interplay Between MicroRNAs and Breast Cancer Therapies: Personalized Therapeutic Potential for HER2-Low Breast Cancer

  2025cites this paper
• BRSK2 plays a role in autophagy and cancer cell growth and survival under nutrient deprivation stress via the PIK3C3 pathway

  2025cites this paper
• Drug repurposing identifies novel Wee1 kinase inhibitors for triple negative breast cancer therapeutics.

  2025cites this paper
• Novel benzoxazole-based hybrids as multi-target inhibitors of aromatase, EGFR, and PI3K with potential anti-breast cancer activity.

  2025cites this paper
• The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast Cancer

  2025cites this paper
• Regulator of chromosome condensation 1 promotes hepatocellular carcinoma proliferation via cell-division-cycle-associated-8 dependent phosphoinositide 3-kinase/protein kinase B signaling

  2025cites this paper
• Transcriptome analysis identifies the NR4A subfamily involved in the alleviating effect of folic acid on mastitis induced by high concentration of Staphylococcus aureus lipoteichoic acid

  2024cites this paper
• Long non-coding RNAs and their role in breast cancer pathogenesis and drug resistance: Navigating the non-coding landscape review.

  2024cites this paper
• Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis

  2024cites this paper
• Brucea javanica derived exosome-like nanovesicles deliver miRNAs for cancer therapy.

  2024cites this paper
• In Silico Study of Compounds from Nanoherbal Jopan (Clibadium surinamense L.) Leaves as Inhibitors AKT1 Interaction

  2024cites this paper
• Design and one-pot synthesis of new substituted pyrrolo[1,2-a]thieno[3,2-e]pyrimidine as potential antitumor agents: in vitro and in vivo studies.

  2024cites this paper
• The Role of Autophagy in Breast Cancer Metastasis

  2023cites this paper
• RBFOX2 confers tumor growth by PI3K/AKT and MAPK signaling in gastric cancer

  2023cites this paper
• Protein degradation: expanding the toolbox to restrain cancer drug resistance

  2023cites this paper
• Safety and Toxicology Study of Hu7691, a Novel AKT Inhibitor, following Oral Administration in Rats

  2023cites this paper
• Role of EGFR and FASN in breast cancer progression

  2023cites this paper
• Biomarkers based on multiplatform comprehensive analysis: A systematic analysis of Geng-Nian-Shu in perimenopausal syndrome.

  2023cites this paper
• Early effects of lipoteichoic acid from Staphylococcus aureus on milk production-related signaling pathways in mouse mammary epithelial cells.

  2022cites this paper
• Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer

  2022influential citation
• Molecular perspective on targeted therapy in breast cancer: a review of current status

  2022cites this paper
• Sodium cantharidate promotes autophagy in breast cancer cells by inhibiting the PI3K–Akt–mTOR signaling pathway

  2022cites this paper
• Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies

  2021influential citation
• Precision Medicine in Cancer

  2021cites this paper
• Autophagy-mediated tumor cell survival and progression of breast cancer metastasis to the brain

  2021cites this paper
• The Correlation of Mutations and Expressions of Genes within the PI3K/Akt/mTOR Pathway in Breast Cancer—A Preliminary Study

  2021cites this paper
• Knockdown of AKT3 Activates HER2 and DDR Kinases in Bone-Seeking Breast Cancer Cells, Promotes Metastasis In Vivo and Attenuates the TGFβ/CTGF Axis

  2021cites this paper
• MRPL13 Promotes Tumor Cell Proliferation, Migration and EMT Process in Breast Cancer Through the PI3K-AKT-mTOR Pathway

  2021cites this paper
• Current trends in the treatment of HR+/HER2+ breast cancer.

  2021cites this paper
• Autophagy Triggers Tamoxifen Resistance in Human Breast Cancer Cells by Preventing Drug-Induced Lysosomal Damage

  2021cites this paper
• Carnosic Acid Induces Apoptosis and Inhibits Akt/mTOR Signaling in Human Gastric Cancer Cell Lines

  2021cites this paper
• Central and peripheral emetic loci contribute to vomiting evoked by the Akt inhibitor MK-2206 in the least shrew model of emesis.

  2021cites this paper
• High expression levels of centromere protein A plus upregulation of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling pathway affect chemotherapy response and prognosis in patients with breast cancer

  2021cites this paper
• PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma

  2021cites this paper
• Xihuang Pill inhibits the development of DMBA combined estrogen and progesterone induced breast precancerous lesions rats by PI3K/AKT/mTOR signaling pathway

  2021cites this paper
• AKT in Bone Metastasis of Solid Tumors: A Comprehensive Review

  2021cites this paper
• Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

  2021cites this paper
• Structural Aspects of mTOR Inhibitors: In Progress to Search Potential Compounds.

  2021cites this paper
• LPS/TLR4 pathways in breast cancer: insights into cell signalling.

  2021cites this paper
• Exploring the selective mechanism of inhibitors towards different subtypes of class I PI3K

  2021cites this paper
• Targeting lysosomes in human disease: from basic research to clinical applications

  2021cites this paper
• Tamoxifen and the PI3K Inhibitor: LY294002 Synergistically Induce Apoptosis and Cell Cycle Arrest in Breast Cancer MCF-7 Cells

  2020cites this paper
• CUDC-907 enhances TRAIL-induced apoptosis through upregulation of DR5 in breast cancer cells

  2020cites this paper
• Clinical significance and prognostic analysis of the phosphorylation levels of Akt proteins in varying molecular subtypes of breast cancer

  2020cites this paper
• MicroRNA-494 suppresses hypoxia/reoxygenation-induced cardiomyocyte apoptosis and autophagy via the PI3K/AKT/mTOR signaling pathway by targeting SIRT1

  2020cites this paper
• Role of PI3K/Akt/GSK-3 Pathway in Emesis and Potential New Antiemetics

  2020cites this paper
• Herbal cake-partitioned moxibustion inhibits colonic autophagy in Crohn’s disease via signaling involving distinct classes of phosphatidylinositol 3-kinases

  2020cites this paper
• Inhibition of the PI3K-AKT-mTOR pathway suppresses the adipocyte-mediated proliferation and migration of breast cancer cells

  2020cites this paper
• Akt isoform-specific effects on thyroid cancer development and progression in a murine thyroid cancer model

  2020cites this paper
• Association of an anaplastic lymphoma kinase pathway signature with cell de‐differentiation, neoadjuvant chemotherapy response, and recurrence risk in breast cancer

  2020influential citation
• An Anaplastic Lymphoma Kinase Pathway Signature is associated with Cell De-differentiation, Neoadjuvant Response and Recurrence Risk in Breast Cancer

  2019cites this paper
• Inhibitory effects of petasin on human colon carcinoma cells mediated by inactivation of Akt/mTOR pathway

  2019cites this paper
• β-Thujaplicin inhibits basal-like mammary tumor growth by regulating glycogen synthase kinase-3β/β-catenin signaling.

  2019cites this paper
• Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells.

  2019cites this paper
• NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non‐inflammatory breast cancers

  2019cites this paper
• EHMT2 promotes the development of prostate cancer by inhibiting PI3K/AKT/mTOR pathway.

  2019cites this paper
• DJ-1/PARK7 inhibits high glucose-induced oxidative stress to prevent retinal pericyte apoptosis via the PI3K/AKT/mTOR signaling pathway.

  2019cites this paper
• Autophagy Function and Dysfunction: Potential Drugs as Anti-Cancer Therapy

  2019cites this paper
• PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges.

  2019cites this paper
• Combined mTOR/MEK inhibition prevents proliferation and induces apoptosis in NF2-mutant tumors.

  2019cites this paper
• Efeito do kaempferol sobre o desenvolvimento in vitro de folículos ovarianos ovinos

  2018influential citation
• World Journal of Gastrointestinal Oncology

  year unknowncites this paper